Clinical trials: Mononegavirales Infections
Rabies Post-exposure Prophylaxis
SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
This study is a randomized, double-blind, active-controlled design. The goal is to evaluate the safety, pharmacokinetics and pharmacodynamic of SYN023 in combination with rabies vaccine in healthy participants under 18 years of…
- Trial name
- NCT07342257
- Testing
- SYN023, Rabies Vaccine, HRIG
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Rabies Virus Infection
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
- Trial name
- NCT06548139
- Testing
- Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg, Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg, Rabies Human Immunoglobulin (HRIG)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
HIV Infections, Hepatitis B
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in…
- Conditions
- HIV Infections, Hepatitis B, Measles, Pneumococcal Infections
- Trial name
- NCT00013871
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent)
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infection
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
The primary objectives of the study were: To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus.
- Trial name
- VAD00001 (NCT04491877)
- Testing
- RSV vaccine formulation 1, RSV vaccine formulation 2
- Where
- 29 sites in United States, Chile and 1 more
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles
Early Waning of Maternal Measles and Meningitis C Antibodies
Maternal antibodies (measles and meningitis C) may wane in the first six months after birth. Geometric mean titers(GMTs) of measles and meningitis C. Follow-up on 0 month, 3rd month,5th month and 7th month after birth.
- Trial name
- EWMM (NCT02219061)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangzhou Center for Disease Control and Prevention
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at…
- Trial name
- NCT05590403
- Testing
- RSVPreF3 OA investigational vaccine
- Volunteers
- 1,544 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV)
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
Phase 1 clinical trial to evaluate the safety of RSV-1 and RSV-2 vaccines in healthy adults aged 19 to 80 years who have voluntarily given written consent to participate in this study.
- Trial name
- EuRSV (NCT06216093)
- Testing
- EuRSV
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
- Trial name
- NCT02864628
- Testing
- MVA-BN-RSV
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Respiratory Syncytial Virus Infections
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
In this randomised, placebo-controlled, double-blind Phase 2a study, healthy male and female participants 18-50 years of age will be given an investigational RSV vaccine (RSVpreF) and challenged with RSV one month later.
- Trial name
- NCT04785612
- Testing
- RSVPreF
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hvivo
Respiratory Syncytial Virus Infections
Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.
- Trial name
- NCT01797419
- Testing
- GS-5806
- Where
- 9 sites in Australia
- Sponsor
- Gilead Sciences
Hemorrhagic Fever, Ebola
Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of the HPIV3-EbovZ GP Ebola vaccine candidate in healthy adults.
- Trial name
- NCT02564575
- Testing
- HPIV3-EbovZ GP Vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients
Respiratory Syncytial Virus - RSV Protocol
The goal of this clinical research study is to learn if ribavirin can help to control RSV in patients with immune systems that have been weakened by a stem cell transplant.
- Conditions
- Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia
- Trial name
- NCT01502072
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Rabies
Immunity Persistence After Abridged Intradermal Rabies PEP
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP).
- Trial name
- RESIST-3 (NCT04829630)
- Testing
- rabies vaccine
- Where
- 2 sites in Cambodia, Madagascar
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
RSV Infection
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b.
- Trial name
- NCT03691623
- Testing
- EDP-938 Dose 1, EDP-938 Dose 2, EDP-938 Dose 3
- Where
- United Kingdom
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Rabies (Healthy Volunteers)
Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.
A multicentre, open label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens (2 x 1IM regimen, 2 x 2 ID regimen, 1 x 2 ID regimen) when administering a single-dose…
- Trial name
- BAZOOKA_221 (NCT07455318)
- Testing
- Booster vaccination
- Where
- 6 sites in Belgium
- Volunteers
- 561 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Severe Respiratory Syncytial Virus Infection
Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease
Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that…
- Trial name
- NCT01075178
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 2,036 people
- Sponsor
- Abbott
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
The aim of this study is to assess the immunogenicity, safety and reactogenicity of the RSV PreFusion protein 3 older adult (RSVPreF3 OA) investigational vaccine when co-administered with an adjuvanted quadrivalent influenza (FLU…
- Trial name
- NCT05568797
- Testing
- RSVPreF3 OA vaccine, FLU vaccine
- Where
- 37 sites in Belgium, Finland and 3 more
- Volunteers
- 1,045 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies Virus Infection
Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
rabies mab CBB 1 is mainly used for passive immunization of patients bitten or scratched by rabies or other animals carrying rabies virus, this study mainly studies the safety, tolerability, pharmacokinetics, neutralizing…
- Trial name
- NCT05832073
- Testing
- Natural full human monoclonal antibody CBB 1 injection, Rabies Human Immunoglobulin (HRIG), Lyophilized rabies vaccine for human use (Vero cells)
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Ebola Virus Disease
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.
- Trial name
- NCT02718469
- Testing
- Ebola Vaccine - low dose, Ebola Vaccine - mid dose, Ebola Vaccine - high dose
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Auro Vaccines LLC